Summary
IMvigor010 was a phase 3 randomised controlled trial comparing adjuvant atezolizumab with observation in patients with completely resected muscle-invasive urothelial carcinoma. The trial, conducted across multiple centres, sought to determine whether post-operative immunotherapy could improve survival outcomes compared to standard surveillance. This represents one of several large oncology trials testing immune checkpoint inhibitors in the adjuvant setting for solid malignancies.
UK applicability
Findings from this international multicentre trial would be directly applicable to UK oncology practice and NHS Cancer Drugs Fund considerations for treatment of muscle-invasive bladder cancer. UK urologists and oncologists would use these results to inform adjuvant treatment decisions for eligible patients post-cystectomy.
Key measures
Disease-free survival; overall survival; recurrence-free interval; adverse event rates
Outcomes reported
The study evaluated disease-free survival and overall survival in patients with muscle-invasive urothelial carcinoma receiving adjuvant atezolizumab (an immune checkpoint inhibitor) versus observation following surgical resection.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.